Orgenesis Inc.

ORGS Healthcare Biotechnology

Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.

0.06 0.06 Infinity
Market cap
$5.7M
P/E
0.0×
Fwd P/E
1.0×
Dividend yield
—
F-score
3/9
Altman Z
−352.42
Beneish M
n/a
Dividend safety
n/a
Dec '24 Sep '24 Jun '24 Mar '24 Older periods
Piotroski F-Score
3 3 4 1

+8 more TTM periods

ROE
164.62% 175.12% 203.46% 478.19%
ROA
(605.73%) (145.76%) (119.30%) (79.92%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
188.28% 184.72% 215.72% 393.45%
Average Days of Receivables
14.11 65.37 132.33 169.05
Free Cash Flow per Share
(4.12) (3.34) (3.23) (3.93)
Free Cash Flow
(17.34) (15.74) (12.54) (13.05)
Capital Expenditures
(0.26) (0.26) (0.50) (1.01)
Other line items
Cash ROIC
86.03% 205.23% 362.31% 1,348.45%
Accounts Receivable Turnover
3.53 1.40 1.09 0.05
Accounts Payable Turnover
0.20 0.27 (0.19) 0.30
Inventory Turnover
0.00 0.00 0.00 38.44
Average Days of Payables
2,484.39 2,014.75 (3,025.80) 1,922.76
Days of Inventory on Hand
0.00 0.00 0.00 3.99
Tax Rate
0.00 0.00 0.01 0.01
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
1,432.08% 1,437.82% 1,738.22% 5,229.11%
Share Based Compensation of Revenue
308.60% 292.66% 164.35% 116.45%
Interest Coverage
(8.82) (9.54) (7.93) (16.09)
Operating CF/Net income
0.35 0.45 0.41 0.29
Depreciation/Fixed assets
3.61 0.12 0.09 0.08
Capex/Depreciation
(0.13) (0.14) (0.34) (0.74)
Revenue per Share
0.25 0.19 0.17 0.16
Operating CF per Share
(4.06) (3.28) (3.10) (3.63)
Capex per Share
(0.06) (0.06) (0.13) (0.31)
Capex to Sales
0.25 0.29 0.76 1.92

Fold the line items

Columns are period end dates